Opinion

Video

Value of PD-L1 Biomarker in NPC

Author(s):

Barbara Burtness, MD,Victoria M. Villaflor, MD

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Video content above is prompted by the following:

  • What is the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma?
Related Videos
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
David Rimm, MD, PhD
Related Content
Maurie Markman, MD, president, Medicine & Science, City of Hope Atlanta, Chicago, and Phoenix
December 10th 2024

The Ongoing Debate: Progression-Free vs Overall Survival as the Primary Study Outcome in Therapeutic Cancer Trials

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Glenn J. Hanna, MD, director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program), director of Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute; and an associate professor of medicine Harvard Medical School
December 5th 2024

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17